Effects of diet and serotonergic agonist on hepatic apolipoprotein B-100 secretion and endothelial function in obese men.
We studied the effects of a hypocaloric diet with or without a serotonergic agonist (dexfenfluramine, Df) on the hepatic secretion of very-low-density-lipoprotein (VLDL) apoB and endothelial function of the forearm microcirculation in 20 viscerally obese men. The kinetics of VLDL apoB were studied using an infusion of 1-((13)C)-leucine. Isotopic enrichment of apo B was measured using gas-chromatography mass spectrometry, and a multicompartmental model was used to estimate kinetic functions. Forearm vasodilatation was measured following an ischaemic stimulus using strain-gauge plethysmography, and visceral adipose tissue mass using magnetic resonance imaging. Compared with leaner subjects, the obese men had significantly higher hepatic apoB secretion (p<0.05) and lower forearm flow debt repayment (p<0.001). Both treatments produced similar decreases (p<0.05) in body weight, waist circumference, visceral adipose tissue and fasting plasma insulin. With diet alone, there was a significant decrease (p<0.05) in the plasma concentration and pool size hepatic secretion rate of VLDL apoB, as well as a significant increase (p<0.05) in post-ischaemic flow debt repayment. With diet plus Df, there were parallel responses in these variables, but only decreased forearm vascular resistance (p<0.05) was statistically significant. Combining both data sets, there was a highly significant reduction in hepatic apoB secretion rate (20. 9+/-2.0 vs. 14.7+/-1.6 mg/kg fat-free mass/day, p=0.005), as well as an increase in both maximal forearm blood flow (16.8+/-7.5 vs. 22. 2+/-8.5 ml/100 ml/min, p=0.006) and flow debt repayment (3.5+/-2.1 vs. 5.4+/-2.8 ml/100 ml, p=0.01), and a decrease in vascular resistance (6.7+/-3.7 vs. 5.1+/-4.4 mmHg/ml/100 ml/min, p=0.007). Obese men have increased hepatic secretion of apoB and endothelial dysfunction of the forearm microcirculation, and decreasing their visceral adipose tissue mass by diet (with or without a serotonergic agonist) improves these abnormalities. This may provide a mechanistic basis for the reduction in cardiovascular risk in obese patients who lose weight.
Watts
G F
GF
University Department of Medicine and Western Australian Heart Research Institute, University of Western Australia, Royal Perth Hospital, Perth, Australia. gfwatts@cyllene.uwa.edu.au
Herrmann
S
S
Riches
F M
FM
D001055:Apolipoproteins B / Q000096:biosynthesis*; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D016022:Case-Control Studies; D020372:Dexfenfluramine / Q000627:therapeutic use*; D004038:Diet, Reducing; D004311:Double-Blind Method; D004730:Endothelium, Vascular; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007328:Insulin / Q000097:blood; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy; D010991:Plethysmography; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D014664:Vasodilation / Q000187:drug effects
D001055:Apolipoproteins B; D007328:Insulin; D017366:Serotonin Receptor Agonists; D020372:Dexfenfluramine